Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials

Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials

Abstract Background Patients with moderate‐to‐severe atopic dermatitis (AD) refractory to topical therapy might require treatment with systemic therapies, including biologics. Objectives To assess the efficacy and safety of abrocitinib monotherapy in patients who previously received systemic therapi...

Full description

Bibliographic Details
Main Authors: Melinda J. Gooderham, Michael R. Ardern‐Jones, Emma Guttman‐Yassky, Mahreen Ameen, Eric L. Simpson, Gary Chan, Pinaki Biswas, Wing S. Chiu, Melissa Watkins
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:JEADV Clinical Practice
Subjects:
atopic dermatitis
biologics
eczema
immunomodulatory therapies
Online Access:https://doi.org/10.1002/jvc2.203

Internet

https://doi.org/10.1002/jvc2.203

Similar Items